Novelion Therapeutics completes reverse stock split
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Novelion Therapeutics Inc. completed a planned 1-to-5 reverse stock split.
The company will now have 18,530,700 shares issued and outstanding with trading to resume on Nasdaq on Dec. 19 and the Toronto Stock Exchange on Dec. 21.
